Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Buchert

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Biomedicines|March 29, 2023
Structure-Guided Prediction of the Functional Impact of DCLK1 Mutations on TumorigenesisAnnalisa L E Carli, Joshua M Hardy, Hanadi Hoblos, et al.
Journal of Cellular Physiology|October 3, 2006
AF6/s-afadin is a dual residency protein and localizes to a novel subnuclear compartmentMichael Buchert, Carole Poon, James A J King, et al.
Biomedicines|October 28, 2023
A Mouse Model for the Rapid and Binomial Assessment of Putative WNT/β-Catenin Signalling InhibitorsJanson Tse, Ryan O'Keefe, Angela Rigopolous, et al.
Genesis (New York, N.Y. : 2000)|February 8, 2017
Generation of an inducible mouse model to reversibly silence Stat3Mariah G Alorro, Thomas P Pierce, Moritz F Eissmann, et al.
Cancers|January 21, 2022
Onco-miR-21 Promotes Stat3-Dependent Gastric Cancer ProgressionJanson Tse, Thomas Pierce, Annalisa L E Carli, et al.
Gastroenterology|March 31, 2009
The symplekin/ZONAB complex inhibits intestinal cell differentiation by the repression of AML1/Runx1Michael Buchert, Charbel Darido, Ebba Lagerqvist, et al.
Molecular Cancer Therapeutics|January 9, 2014
Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in miceEmma Stuart, Michael Buchert, Tracy Putoczki, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Symplekin promotes tumorigenicity by up-regulating claudin-2 expressionMichael Buchert, Marina Papin, Caroline Bonnans, et al.
Cancer Research|June 4, 2008
Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cellsCharbel Darido, Michael Buchert, Julie Pannequin, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Circulating inflammatory ILC2s as a biomarker of gastric cancer progressionRyan N O'Keefe, Kiruthiga Raghunathan, Moritz F Eissmann, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Biomedicines|March 29, 2023
Structure-Guided Prediction of the Functional Impact of DCLK1 Mutations on TumorigenesisAnnalisa L E Carli, Joshua M Hardy, Hanadi Hoblos, et al.
Journal of Cellular Physiology|October 3, 2006
AF6/s-afadin is a dual residency protein and localizes to a novel subnuclear compartmentMichael Buchert, Carole Poon, James A J King, et al.
Biomedicines|October 28, 2023
A Mouse Model for the Rapid and Binomial Assessment of Putative WNT/β-Catenin Signalling InhibitorsJanson Tse, Ryan O'Keefe, Angela Rigopolous, et al.
Genesis (New York, N.Y. : 2000)|February 8, 2017
Generation of an inducible mouse model to reversibly silence Stat3Mariah G Alorro, Thomas P Pierce, Moritz F Eissmann, et al.
Cancers|January 21, 2022
Onco-miR-21 Promotes Stat3-Dependent Gastric Cancer ProgressionJanson Tse, Thomas Pierce, Annalisa L E Carli, et al.
Gastroenterology|March 31, 2009
The symplekin/ZONAB complex inhibits intestinal cell differentiation by the repression of AML1/Runx1Michael Buchert, Charbel Darido, Ebba Lagerqvist, et al.
Molecular Cancer Therapeutics|January 9, 2014
Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in miceEmma Stuart, Michael Buchert, Tracy Putoczki, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Symplekin promotes tumorigenicity by up-regulating claudin-2 expressionMichael Buchert, Marina Papin, Caroline Bonnans, et al.
Cancer Research|June 4, 2008
Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cellsCharbel Darido, Michael Buchert, Julie Pannequin, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Circulating inflammatory ILC2s as a biomarker of gastric cancer progressionRyan N O'Keefe, Kiruthiga Raghunathan, Moritz F Eissmann, et al.
Pageof 5